Gainey McKenna & Egleston Announces the Proposed Class Action Settlement on Behalf of Purchasers of Kiromic BioPharma Inc. common stock - KRBPQ

A proposed class action settlement of $1,225,000 has been approved by the U.S. District Court for the Southern District of New York on behalf of purchasers of Kiromic BioPharma Inc. common stock. The settlement resolves allegations that company defendants made false and misleading statements during the class period from June 25, 2021 to February 2, 2022. A fairness hearing is scheduled for December 17, 2026.